Clin Cancer Res 2020 Sep 1
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Related Questions
Biopsy of other sites is more consistent with carcinoid tumor.
New answer by Medical Oncologist at UH Seidman Cancer Center, Case Western Reserve University (May 19, 2021)
Most of these patients end up having aggressive HCC or cholangio rather than real high grade G3 NET or NEC. So definitely agree with path review, preferably with a NET patho...
For this example, Ki-67 of 80, MSS, low TMB
New answer by Medical Oncologist at UH Seidman Cancer Center, Case Western Reserve University (September 7, 2022)
This is a great question. I will try to summarize the current data for treating poorly differentiated GEP-NEC.
However, high-grade poorly differentiated GEP neuroendocrine ca...